Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2006 1
2007 1
2008 1
2010 1
2012 1
2013 3
2014 1
2015 3
2016 2
2017 1
2018 1
2019 1
2020 1
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6.
Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ. Takahashi PY, et al. Pharmgenomics Pers Med. 2017 Feb 14;10:39-47. doi: 10.2147/PGPM.S114211. eCollection 2017. Pharmgenomics Pers Med. 2017. PMID: 28243137 Free PMC article.
BACKGROUND: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and other environmental exposures, but it is unclear whether the CYP2D6 phenotype is associated with adverse health outcomes. ...CONCLUSIO …
BACKGROUND: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and o …
Complexities of CYP2D6 gene analysis and interpretation.
Gaedigk A. Gaedigk A. Int Rev Psychiatry. 2013 Oct;25(5):534-53. doi: 10.3109/09540261.2013.825581. Int Rev Psychiatry. 2013. PMID: 24151800 Review.
Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and bioactivation of about 25% of clinically used drugs including many antidepressants, antipsychotics and opioids. CYP2D6 activity is highly variably ranging from no
Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and bioactivation of about 25% of
Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.
Söderberg Löfdal KC, Andersson ML, Gustafsson LL. Söderberg Löfdal KC, et al. Drugs. 2013 May;73(6):533-43. doi: 10.1007/s40265-013-0036-0. Drugs. 2013. PMID: 23605691 Review.
The bioavailability is higher than for morphine and less variable. Oxycodone is primarily metabolized in the liver by the cytochrome P450 (CYP) enzymes with CYP3A as the major metabolic pathway and CYP2D6 as the minor metabolic pathway to …
The bioavailability is higher than for morphine and less variable. Oxycodone is primarily metabolized in the liver by the cytochro
Pharmacogenetics of opioid response.
Somogyi AA, Coller JK, Barratt DT. Somogyi AA, et al. Clin Pharmacol Ther. 2015 Feb;97(2):125-7. doi: 10.1002/cpt.23. Epub 2014 Dec 9. Clin Pharmacol Ther. 2015. PMID: 25670515
For opioids requiring CYP2D6 O-demethylation to active metabolites, poor metabolizers have reduced metabolite formation and minimal pain reduction. Clinically, this has only reliably been shown for tramadol. Ultra-rapid metabolizers have an increased
For opioids requiring CYP2D6 O-demethylation to active metabolites, poor metabolizers have reduced metabolite formation and mi …
Applications of CYP450 testing in the clinical setting.
Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Samer CF, et al. Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Mol Diagn Ther. 2013. PMID: 23588782 Free PMC article. Review.
CYP2D6 PM phenotype has been associated with an increased risk of toxicity of metoprolol, timolol, carvedilol and propafenone. ...CYP2C19 is involved in the metabolism of several antidepressants. As a result of an increased risk
CYP2D6 PM phenotype has been associated with an increased risk of toxicity of metoprolol, timolol, carvedilol an
Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs.
Chanfreau-Coffinier C, Tuteja S, Hull LE, MacDonald S, Efimova O, Bates J, Voora D, Oslin DW, DuVall SL, Lynch JA. Chanfreau-Coffinier C, et al. Pain. 2022 Dec 1;163(12):2390-2397. doi: 10.1097/j.pain.0000000000002637. Epub 2022 Mar 23. Pain. 2022. PMID: 35319502
We sought to determine the potential impact of PGx testing on the care of Veterans with noncancer pain prescribed opioids metabolized by CYP2D6 (codeine, hydrocodone, or tramadol). A retrospective analysis was performed within the Veterans Health Administration eval …
We sought to determine the potential impact of PGx testing on the care of Veterans with noncancer pain prescribed opioids metabolized
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, Truong TM, van Wijk XMR, Yeo KJ, Malec M, Ratain MJ, O'Donnell PH. Reizine N, et al. Oncologist. 2021 Nov;26(11):e2042-e2052. doi: 10.1002/onco.13953. Epub 2021 Sep 19. Oncologist. 2021. PMID: 34423496 Free PMC article.
Patients with intermediate and/or poor CYP2D6 metabolizer status do not adequately convert codeine, tramadol, and hydrocodone into active compounds, with resulting increased risk of inadequate analgesia. This study showed that patients with canc …
Patients with intermediate and/or poor CYP2D6 metabolizer status do not adequately convert codeine, tramadol, and hydrocodone …
[Pharmacoresistance to psychotropic drugs in children and adolescents: Pharmacogenetic anomalies of cytochrome P450 2D6].
David A, Fernandez A, Menard ML, Dor E, Leali G, Maria F, Cruzel C, Askenazy F, Verstuyft C, Thümmler S. David A, et al. Encephale. 2021 Jun;47(3):227-234. doi: 10.1016/j.encep.2020.09.010. Epub 2021 Feb 4. Encephale. 2021. PMID: 33551122 French.
OBJECTIVES: Some patients in child and adolescent psychiatry present resistance to psychotropic drugs, often resulting in polytherapy, an increased risk of adverse events, and more frequent and longer hospitalisation. Psychotropic drugs are mainly meta …
OBJECTIVES: Some patients in child and adolescent psychiatry present resistance to psychotropic drugs, often resulting in polytherapy, an …
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
Nijenhuis M, Soree B, Jama WOM, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Rongen GA, van Schaik RHN, Swen JJ, Touw D, van der Weide J, van Westrhenen R, Deneer VHM, Risselada A. Nijenhuis M, et al. Eur J Hum Genet. 2023 Dec;31(12):1364-1370. doi: 10.1038/s41431-022-01262-z. Epub 2022 Dec 12. Eur J Hum Genet. 2023. PMID: 36509836
With decreasing CYP2D6 enzyme activity, the exposure to atomoxetine and the risk of atomoxetine induced side effects increases. So, for patients with genetically absent CYP2D6 enzyme activity (CYP2D6 poor metabolisers), the DPWG recommend …
With decreasing CYP2D6 enzyme activity, the exposure to atomoxetine and the risk of atomoxetine induced side effects …
A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts.
Peñas-Lledó EM, Guillaume S, de Andrés F, Cortés-Martínez A, Dubois J, Kahn JP, Leboyer M, Olié E, LLerena A, Courtet P. Peñas-Lledó EM, et al. Transl Psychiatry. 2022 Oct 18;12(1):451. doi: 10.1038/s41398-022-02140-4. Transl Psychiatry. 2022. PMID: 36257936 Free PMC article.
The risk of reattempts was higher for CYP2D6 ultrarapid (AS > 2) metabolizers (beta = 0.561, p = 0.005) and violent suicide survivors (beta = -0.219, p = 0.042) if the attempt occurred during the first 6-month period, individuals with an i
The risk of reattempts was higher for CYP2D6 ultrarapid (AS > 2) metabolizers (beta = 0.561, p = 0.005 …
23 results